$IRME | OTCQB PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdown
IR-MED a developer of noninvasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, announces positive interim results from its ongoing U.S. clinical study of PressureSafe™, a handheld infrared spectroscopy device for assessment of pressure injuries (PIs), including deep tissue injuries (DTIs) before visible skin breakdown - a breakthrough especially significant for patients with darker skin tones
https://marketwirenews.com/news-releases/ir-med-reports-positive-interim-results-from-u-s-cli-6790475701371317.html
$IRME IR-Med Inc. DD
IIR-Med, Inc. and its consolidated Subsidiary, IR. Med Ltd. is an innovative med-tech company focused on leveraging Infra-Red light for medical application. IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue.
Read full $IRME DD: https://x.com/whiskey_lima729/status/1929525388671128024
